Accurate Use of Prostate-Specific Antigen in Determining Risk of Prostate Cancer

Journal for Nurse Practitioners

Volumn 6, Issue 3, 2010, Pages 177-184

  Angie, Michelle A ^a  

^a NONE

Author keywords

Prostate; prostate cancer; PSA; screening

Indexed keywords

EID: 77649210711     PISSN: 15554155     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurpra.2009.11.012     Document Type: Article

References (30)

1. Loeb S., Han M., and Catalona W.J. Prostate-specific antigen and prostate cancer screening. In: Jones J.S. (Ed). Prostate biopsy: indications, techniques and complications (2008), Humana Press, Totowa, NJ 14-24
2. Thompson I.M., Pauler D.K., Goodman P.J., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level greater than or equal to 4.0 ng per milliliter. N Engl J Med 350 22 (2004) 2239
3. Thompson I.M., and Ankerst D.P. Prostate-specific antigen in the early detection of prostate cancer. CMAJ JAMC 176 13 (2007) 1853-1858
4. Nielsen M.E., and Partin A.W. The role of complexed prostate-specific antigen in prostate cancer screening. In: Jones J.S. (Ed). Prostate biopsy: indications, techniques, and complications (2008), Humana Press Inc, Totowa, NJ
5. Rao A.R., Motiwala H.G., and Karim O. The discovery of prostate-specific antigen. BJU Int 101 1 (2008) 5-10
6. Federal Food and Drug Administration. FDA Approves Test for Prostate Cancer. Available at: http://www.scienceblog.com/community/older/archives/M/1/fda0245.htm Accessed October 25, 2009
7. Sandhu J.S. Management of elevated prostate-specific antigen in men with nonbacterial chronic prostatitis. Curr Urol Rep 10 (2009) 302-306
8. Canto E.I., and Slawin K.M. Newly recognized forms of prostate-specific antigen and emerging molecular markers. In: Jones J.S. (Ed). Prostate biopsy: indications, techniques, and complications (2008), Humana Press, Totowa, NJ 40-56
9. Richardson T.D., and Oesterling J.E. Age-specific reference ranges for serum prostate-specific antigen. Urol Clin North Am 24 2 (1997) 339-351
10. Etzioni R.D., Howlander N., Sahw P.A., et al. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. J Urol 174 (2005) 877-881
11. Potts J. Prospective identification of National Institutes of Health category IV prostatitis in men with elevated prostate specific antigen. J Urol 164 5 (2000) 1550-1553
12. Ulleryd P., Zackrisson B., Aus G., Bergdahl S., Hugosson J., and Sandberg T. Prostatic involvement in men with febrile urinary tract infection as measured by serum prostate-specific antigen and transrectal ultrasonography. BJU Int 84 4 (1999) 470-474
13. Zackrisson B., Ulleryd P., Aus G., Lilja H., Sandberg T., and Hugosson J. Evolution of free, complexed, and total serum prostate-specific antigen and their ratios during 1 year of follow-up of men with febrile urinary tract infection. Urology 62 6 (2003) 287 281
14. Bañez L.L., Hamilton R.J., Partin A.W., et al. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA 298 19 (2007) 2275-2280
15. Werny D.M., Thompson T., Saraiya M., et al. Obesity is negatively associated with prostate-specific antigen in U.S. men, 2001-2004. Cancer Epidemiol Biomarkers Prev 16 1 (2007) 70-76
16. Rundle A., and Neugut A.I. Obesity and screening PSA levels among men undergoing an annual physical exam. Prostate 68 (2008) 373-380
17. Hutterer G., Perrotte P., Gallina A., et al. Body mass index does not predict prostate-specific antigen or percent free prostate-specific antigen in men undergoing prostate cancer screening. Eur J Cancer 43 7 (2007) 1180-1187
18. Link R.E., Shariate S.F., Nguyen C.V., et al. Variation in prostate specific antigen results from 2 different assay platforms: clinical impact on 2,304 patients undergoing prostate cancer screening. Clin Urol 171 6, Part 1 (2004) 2234-2238
19. National Institutes of Health, and National Cancer Institute. Prostate Cancer Screening. Available at: http://www.cancer.gov/cancertopics/pdq/screening/prostate/patient/ Accessed October 25, 2009.
20. Center for Disease Control. Prostate Cancer Screening; A Decision Guide. Available at: http://www.cdc.gov/cancer/Prostate/publications/decisionguide/ Accessed October 25, 2009.
21. Presti J.C., Kane C.J., Shinohara K., and Carroll P.R. Neoplasms of the Prostate Gland. In: Tanagho E.A., and McAninch J.W. (Eds). Smith's general urology. 17th ed. (2008), McGraw Hill, New York (ch. 22).
22. Loeb S., and Schaeffer E.M. Risk factors, prevention and early detection of prostate cancer. Prim Care 36 3 (2009) 603-621
23. Brawley O.W., Ankerst D.P., and Thompson I.M. Screening for prostate cancer. CA Cancer J Clin 59 (2009) 264-273
24. Klotz L., Drachenberg D., Fradet Y., et al. Gleason grading controversies: what the chemoprevention trials have taught us. CUAJ 3 3 Suppl 2 (2009) S115-S120
25. U.S. Preventive Services Task Force. Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement. Available at: http://www.ahrq.gov/clinic/uspstf08/prostate/prostaters.htm Accessed October 25, 2009.
26. Prostate-Specific Antigen Best Practice Statement: 2009 Update. American Urological Association (2009). Available at: http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines/main-reports/psa09.pdf Accessed October 25, 2009.
27. American Cancer Society. American Cancer Society Guidelines for the Early Detection of Cancer. Available at: http://www.cancer.org/docroot/PED/content/PED_2_3X_ACS_Cancer_Detection_Guidelines_36.asp?sitearea=PED Accessed October 25, 2009.
28. Nguyen C.T., Yu C., Moussa A., Kettan M.W., and Jones J.S. Performance of prostate cancer prevention trial risk calculator in a contemporary cohort screened for prostate cancer and diagnosed by extended prostate biopsy. J Urol 183 (2010) 529-533
29. Catalona W.J., Partin A.W., Slawin K.M., et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease. JAMA 279 (1998) 1542-1547
30. Carter H.B. The role of prostate specific antigen velocity in the diagnosis and management of prostate cancer. In: Jones J.S. (Ed). Prostate biopsy: indications, techniques, and complications (2008), Humana Press, Totowa, NJ 57-66